List view / Grid view
Filter the results
Mahfoozur Rahman and Sarwar Beg explain why we need to change tack from traditional formulation-driven development to a target-based approach in order to increase success with anticancer nanomedicine in the clinic.
Antibody drug conjugates are presently recognised as a potent class of targeted anticancer therapies which will result in growth in the market.
A US district court has invalidated Amgen's patent claims for antibodies targeting PCSK9.
Sanofi has won the latest appeal for the patent of its top oncology product, Jevtana (cabazitaxel).
The US District Court has decided in favour of Amgen’s Enbrel, ruling over Sandoz’s Erelzi in a patent conflict.
The US District Court has ruled in favour of Eli Lilly in the Alimta patent lawsuit against Dr. Reddy's Laboratories and Hospira, Inc.
AbbVie has announced that it has resolved its US HUMIRA (adalimumab) litigation with Boehringer Ingelheim.
In a ruling handed down by the UK Supreme Court, Lord Hodge has confirmed that discoveries made through well-established or routine research protocols can be inventive and rewarded with a patent.
In a ruling handed down on 27 March 2019 by the UK Supreme Court, Lord Hodge has confirmed that discoveries made through well-established or routine research protocols can be rewarded with a patent...
29 October 2018 | By Charles River
Timelines, budgets and regulatory constraints have grown alongside that of the Quality Control (QC) lab’s position in drug development. The main goal of the lab and more widely of the manufacturing industry is to increase safety for the end user and guarantee patients’ health...